Catherine Rioufol

1.9k total citations
89 papers, 969 citations indexed

About

Catherine Rioufol is a scholar working on Geriatrics and Gerontology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Catherine Rioufol has authored 89 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Geriatrics and Gerontology, 23 papers in Oncology and 17 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Catherine Rioufol's work include Pharmaceutical Practices and Patient Outcomes (28 papers), Pharmaceutical studies and practices (13 papers) and Patient Safety and Medication Errors (11 papers). Catherine Rioufol is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (28 papers), Pharmaceutical studies and practices (13 papers) and Patient Safety and Medication Errors (11 papers). Catherine Rioufol collaborates with scholars based in France, United States and India. Catherine Rioufol's co-authors include Florence Ranchon, Vérane Schwiertz, Nicolas Vantard, Gilles Salles, Benoît You, Gilles Freyer, Stéphanie Parat, Émilie Hénin, V. Trillet-Lenoir and Claude Dussart and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Catherine Rioufol

79 papers receiving 949 citations

Peers

Catherine Rioufol
Florence Ranchon France
Samuel Limat France
Vérane Schwiertz France
Ana Herranz‐Alonso Spain
Raymond J. Muller United States
Lisa Schulmeister United States
Nicolas Vantard France
Vicente Escudero‐Vilaplana Spain
B. Gourieux France
Ahmed Al‐Jedai Saudi Arabia
Florence Ranchon France
Catherine Rioufol
Citations per year, relative to Catherine Rioufol Catherine Rioufol (= 1×) peers Florence Ranchon

Countries citing papers authored by Catherine Rioufol

Since Specialization
Citations

This map shows the geographic impact of Catherine Rioufol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Rioufol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Rioufol more than expected).

Fields of papers citing papers by Catherine Rioufol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Rioufol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Rioufol. The network helps show where Catherine Rioufol may publish in the future.

Co-authorship network of co-authors of Catherine Rioufol

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Rioufol. A scholar is included among the top collaborators of Catherine Rioufol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Rioufol. Catherine Rioufol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Spanjaart, Anne M., Catherine Rioufol, Delphine Maucort‐Boulch, et al.. (2025). Patient-Reported Outcomes of CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients and Their Impact on Survival. Transplantation and Cellular Therapy. 32(1). 59.e1–59.e13.
3.
4.
Cartron, Guillaume, Catherine Thiéblemont, Isabelle Borget, et al.. (2024). Évaluation en vie réelle du parcours de soins des patients éligibles à un traitement par axicabtagene ciloleucel : cohorte multicentrique IMPA-CT. Bulletin du Cancer. 111(11). 1020–1029.
5.
Boulin, Mathieu, Claire Falandry, Laure de Decker, et al.. (2023). Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: A position paper from SOFOG-SFPO. Critical Reviews in Oncology/Hematology. 190. 104117–104117. 5 indexed citations
6.
Canales, Miguel, Pier Luigi Canonico, Guillaume Cartron, et al.. (2023). Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Frontiers in Medicine. 10. 1128295–1128295. 12 indexed citations
7.
Rioufol, Catherine, et al.. (2023). Pandémie à SARS-COV-2 : implication du pharmacien hospitalier dans la sécurisation de la prise en charge des patients. Annales Pharmaceutiques Françaises. 81(5). 900–908. 1 indexed citations
8.
Baudouin, Anne, et al.. (2023). Cancer outpatients during the COVID-19 pandemic: what Oncoral has to teach us about medical drug use and the perception of telemedicine. Journal of Cancer Research and Clinical Oncology. 149(14). 13301–13310. 2 indexed citations
9.
Huot, Laure, et al.. (2023). Clinical impact and cost‐saving analysis of a comprehensive pharmaceutical care intervention in older patients with cancer. Journal of the American Geriatrics Society. 72(2). 567–578. 3 indexed citations
10.
Grangé, C., Catherine Rioufol, Pierre-Jean Souquet, & Souad Assaad. (2023). Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions. Clinical Pharmacokinetics. 62(11). 1523–1531. 1 indexed citations
11.
Rioufol, Catherine, Nicolas Vantard, Alexandre Teixeira, et al.. (2022). Intravenous route for folate supplementation in a patient with celiac disease treated by pemetrexed-based chemotherapy for non-small-cell lung cancer. Journal of Oncology Pharmacy Practice. 29(3). 750–754.
12.
Saux, Olivia Le, Aurélie Bourmaud, Catherine Rioufol, et al.. (2018). Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients. Cancer Chemotherapy and Pharmacology. 82(2). 319–327. 15 indexed citations
13.
Fargier, Emilie, Nicolas Vantard, Florence Ranchon, et al.. (2017). Évolution du remboursement des anticancéreux inscrits sur la liste en sus : impact financier au sein d’un centre hospitalo-universitaire. Bulletin du Cancer. 104(6). 538–551. 2 indexed citations
14.
Viel, Sébastien, Lorna Garnier, Paul Rouzaire, et al.. (2015). The Basophil Activation Test: A Sensitive Test in the Diagnosis of Allergic Immediate Hypersensitivity to Pristinamycin. International Archives of Allergy and Immunology. 167(2). 94–98. 6 indexed citations
15.
Dupuis‐Girod, Sophie, Évelyne Decullier, Géraldine Samson, et al.. (2014). ELLIPSE Study. mAbs. 6(3). 793–798. 39 indexed citations
16.
Benjamin, L., et al.. (2012). Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. Journal of Medical Economics. 16(1). 96–107. 10 indexed citations
17.
Janoly-Duménil, A., Christopher Bourne, Jacques Luauté, et al.. (2011). Oral anticoagulant treatment – Evaluating the knowledge of patients admitted in physical medicine and rehabilitation units. Annals of Physical and Rehabilitation Medicine. 54(3). 172–180. 18 indexed citations
18.
Ranchon, Florence, Gilles Salles, Hans-Martin Späth, et al.. (2011). Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 11(1). 478–478. 93 indexed citations
19.
Roth, Bradley J., et al.. (2005). Nécrose cutanée induite par fluindione chez un patient déficitaire en protéine C. Journal de Pharmacie Clinique. 24(2). 115–118. 2 indexed citations
20.
Roth, Brett, et al.. (2005). Fluindione-induced skin necrosis in a patient with protein C deficiency. Journal de Pharmacie Clinique. 24(2). 115–118.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Ranchon Breakdown of academic impact, for papers by Samuel Limat Breakdown of academic impact, for papers by Vérane Schwiertz Breakdown of academic impact, for papers by Ana Herranz‐Alonso Breakdown of academic impact, for papers by Raymond J. Muller Breakdown of academic impact, for papers by Lisa Schulmeister Breakdown of academic impact, for papers by Nicolas Vantard Breakdown of academic impact, for papers by Vicente Escudero‐Vilaplana Breakdown of academic impact, for papers by B. Gourieux Breakdown of academic impact, for papers by Ahmed Al‐Jedai
Rankless by CCL
2026